The Male Contraception Quarterly is a summary of market research, important clinical findings, and relevant policy guidance. The Quarterly features letters from men and women explaining why they support the development of new male contraceptives. There is also an ongoing analysis of new survey data designed to characterize the male contraceptive product market.

The Male Contraception Quarterly, Number 1 September - December 2006	Do men want new contraceptives? Do women? Results from an ongoing survey Save the date for the 2nd Future of Male Contraception conference Letters from would-be customers Important clinical findings: Male hormonal contraceptives reliably reversible, Adjudin crosses the blood-testis barrier, Compounds inhibit contractions of the vas deferens Important policy guidance: Male Hormonal Contraception Summit members make clinical trial recommendations, Focus on male contraception R&D recommended to USAID, Family planning critical to attaining the MDGs Male contraceptives in the headlines (14 pages)	260KB
The Male Contraception Quarterly, Number 2/3 January - June 2007	Growing evidence of support for the introduction of new birth control for men Important clinical findings: Sperms' ability to swim as a contraceptive target, RISUG's Phase III clinical trial, Hormonal male contraceptive non-responders, IVD trial underway Important policy news & guidance: WHO says men in China and Italy find male hormonal contraceptive acceptable, Achievement of the Millennium Development Goals depends on family planning Future of Male Contraception conference in Seattle, September 27-28, 2007 (14 pages)	380KB